Background. Familial combined hyperlipidemia (FCHL), the most common genetic form of hyperlipdemia, is characterized by a strong familial clustering and by premature coronary heart disease. The FCHL locus has been mapped to human chromosome 1q21-q23. This region includes the retinoid X receptor gamma (RXRG), a nuclear factor member of the RXR superfamily, which plays important roles in lipid homeostasis. Objective. To investigate the possible role of the RXRG gene in the genetic susceptibility to FCHL. Methods. Variations in RXRG gene were searched by direct sequencing, and the identified SNPs were genotyped by PCR-RFLP in 192 FCHL individuals from 74 families and in 119 controls. Results. We identified 5 polymorphisms in the RXRG gene (rs1128977, rs2651860, rs2134095, rs283696, and rs10918169). Genotyping showed that the A-allele of rs283696 SNP was significantly associated with FCHL (corrected , ). Also the alleles of the rs10918169 and of the rs2651860 SNP were more frequent in FCHL subjects compared to those in controls, although not significantly after correction. When the clinical characteristics of the FCHL subjects were stratified by allele carrier status for each SNP, the rs2651860 SNP was significantly associated with increased levels of LDL-cholesterol and of Apo-B in T-allele carriers . Finally, haplotypes analysis with all 5 SNPs confirmed the significant association of RXRG gene with FCHL. Specifically, the haplotype containing all 3 “at-risk” alleles, significantly associated with FCHL (A-allele of rs283696, G-allele of rs10918169, and T-allele of rs2651860), showed an OR (Odds Ratio) of 2.02, . Conversely, the haplotype without all these 3 alleles was associated with a reduced risk for FCHL ( , ). The “at-risk” haplotype CTTAG was also associated with higher LDL-C . In conclusion, variation in the RXRG gene may contribute to the genetic dyslipidemia in FCHL subjects. 1. Background Familial combined hyperlipidemia (FCHL) is the most common atherogenic disorder of lipid metabolism [1, 2], typically characterized by multiple hyperlipemic phenotypes within the same individual as well as in the same family, where elevated very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) or apolipoprotein B (apoB) can be detected [3–5]. FCHL shows strong genetic susceptibility and an autosomal dominant mode of inheritance with low penetrance [1, 6]. However, most of the underlying genes remain to be elucidated. A previous linkage analysis with markers from ten chromosomal regions that contain lipid-metabolism candidate genes revealed
References
[1]
C. C. Shoulders, E. L. Jones, and R. P. Naoumova, “Genetics of familial combined hyperlipidemia and risk of coronary heart disease,” Human Molecular Genetics, vol. 13, no. 1, pp. R149–R160, 2004.
[2]
P. N. Hopkins, G. Heiss, R. C. Ellison et al., “Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart study,” Circulation, vol. 108, no. 5, pp. 519–523, 2003.
[3]
A. F. Ayyobi, S. H. McGladdery, M. J. McNeely, M. A. Austin, A. G. Motulsky, and J. D. Brunzell, “Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1289–1294, 2003.
[4]
A. D. Sniderman, J. Ribalta, and M. Castro Cabezas, “How should FCHL be defined and how should we think about its metabolic bases?” Nutrition, Metabolism and Cardiovascular Diseases, vol. 11, no. 4, pp. 259–273, 2001.
[5]
M. J. Veerkamp, J. de Graaf, S. J. Bredie, J. C. Hendriks, P. N. Demacker, and A. F. Stalenhoef, “Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 2, pp. 274–282, 2002.
[6]
J. L. Goldstein, H. G. Schrott, W. R. Hazzard, E. L. Bierman, and A. G. Motulsky, “Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia,” Journal of Clinical Investigation, vol. 52, no. 7, pp. 1544–1568, 1973.
[7]
P. Pajukanta, I. Nuotio, J. D. Terwilliger et al., “Linkage of familial combined hyperlipidaemia to chromosome 1q21–q23,” Nature Genetics, vol. 18, no. 4, pp. 369–373, 1998.
[8]
D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995.
[9]
A. I. Shulman and D. J. Mangelsdorf, “Retinoid X receptor heterodimers in the metabolic syndrome,” The New England Journal of Medicine, vol. 353, no. 6, pp. 604–615, 2005.
[10]
H. Knoblauch, A. Busjahn, B. Müller-Myhsok et al., “Peroxisome proliferator-activated receptor γ gene locus is related to body mass index and lipid values in healthy nonobese subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 12, pp. 2940–2944, 1999.
[11]
L. Nanni, F. Quagliarini, F. Megiorni et al., “Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia,” Atherosclerosis, vol. 213, no. 1, pp. 206–211, 2010.
[12]
D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985.
[13]
M. Arca, A. Montali, G. Pigna et al., “Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia,” Metabolism, vol. 56, no. 11, pp. 1534–1541, 2007.
[14]
T. V. Perneger, “What's wrong with Bonferroni adjustments,” British Medical Journal, vol. 316, no. 7139, pp. 1236–1238, 1998.
[15]
A. Nohara, M. A. Kawashiri, T. Claudel et al., “High frequency of a retinoid X receptor γ gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 923–928, 2007.
[16]
W. Pei, H. Baron, B. Müller-Myhsok et al., “Support for linkage of familial combined hyperlipidemia to chromosome 1q21–q23 in Chinese and German families,” Clinical Genetics, vol. 57, no. 1, pp. 29–34, 2000.
[17]
M. I. Dawson and Z. Xia, “The retinoid X receptors and their ligands,” Biochimica et Biophysica Acta, vol. 1821, no. 1, pp. 21–56, 2012.
[18]
W. Krezel, V. Dupé, M. Mark, A. Dierich, P. Kastner, and P. Chambon, “RXRγ null mice are apparently normal and compound RXR α+/？/RXRβ？/？/RXRγ？/？ mutant mice are viable,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 17, pp. 9010–9014, 1996.
[19]
B. R. Haugen, D. R. Jensen, V. Sharma et al., “Retinoid X receptor γ-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet,” Endocrinology, vol. 145, no. 8, pp. 3679–3685, 2004.
[20]
A. Szanto, V. Narkar, Q. Shen, I. P. Uray, P. J. Davies, and L. Nagy, “Retinoid X receptors: X-ploring their (patho)physiological functions,” Cell Death and Differentiation, vol. 11, no. 2, pp. S126–S143, 2004.
[21]
N. Zelcer and P. Tontonoz, “Liver X receptors as integrators of metabolic and inflammatory signaling,” Journal of Clinical Investigation, vol. 116, no. 3, pp. 607–614, 2006.
